Evidence map›Paper›PMID 25356123›Full record

ArticleInternational journal of clinical and experimental medicine2014

Evaluation of prognostic factors and survival results in gastric carcinoma: single center experience from Northeast Turkey.

Emine Canyilmaz, Gulsen Soydemir, Lasif Serdar, Gonca Hanedan Uslu, Asli Sahbaz, Fatma Colak, Mustafa Kandaz, Zumrut Bahat, Adnan Yoney

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emine CanyilmazDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Gulsen SoydemirDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Lasif SerdarDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Gonca Hanedan UsluDepartment of Radiation Oncology, Kanuni Research and Education Hospital Trabzon, Turkey.
Asli SahbazDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Fatma ColakDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Mustafa KandazDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Zumrut BahatDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.
Adnan YoneyDepartment of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University Trabzon, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the prognostic factors affecting overall survival (OS), disease-free survival (DFS), and survival among patients undergoing chemoradiotherapy (CRT) for locally advanced gastric carcinoma.

methodsBetween January 2001 and May 2014, 257 patients who presented to our clinic with a diagnosis of stage I-IIIC gastric cancer were evaluated. The male/female ratio of the cases was 2.02:1 and the median age was 55.16±11.8 (20-80) years. Four of the cases (1.6%) were stage IA, 13 (5.1%) were stage 1B, 41 (16%) were stage IIA, 40 (15.6%) were stage IIB, 50 (19.5%) were stage IIIA, 51 (19.8%) were stage IIIB, and 58 (22.6%) were stage IIIC.

resultsThe mean follow-up time was 22.5 months (3.3-155.0); loco-regional recurrence was noted in 34 (13.2%) patients who underwent postoperative chemoradiotherapy, and metastases were observed in 108 (42%) patients. The median OS duration was 26.7 months (95% confidence interval, 20-33.5) and the 2-, 5-, and 10-year OS was 52.8% (standard error [S.E.] 0.032), 36.1% (S.E. 0.032), and 26.9% (S.E. 0.034) respectively. The median DFS was 53.7 months and the 2-, 5-, and 10-year DFS were 58.9% (S.E. 0.034), 47.4% (S.E. 0.037), and 40.7% (S.E. 0.042), respectively. In multivariate analysis of prognostic factors, advanced T stage (p<0.0001), advanced nodal stage (p=0.001), and surgical margin status (p<0.0001) were related to decreased OS and DFS.

conclusionR1 resection, advanced T stage, and advanced nodal stage were adverse prognostic factors in gastric cancer patients who had undergone CRT after the operation.

Indexed as

Chemoradiotherapygastric cancerstagesurgical margin

Identifiers

PMID25356123
PMCPMC4211773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.